YTEN

Yield10 Bioscience, Inc. (YTEN) | Rumor.io

Yield10 Bioscience

YTEN

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about YTEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 17

Yield10 Bioscience (YTEN) has signed a Memorandum of Understanding and License Agreement with Nufarm, granting a commercial license to Omega-3 assets for producing oil in Camelina.
Nufarm will pay up to USD $5 million for the license and has agreed to negotiate exclusively with Yield10 for the sale of Yield10's remaining assets, subject to shareholder approval.
The deal aims to enable a land-based supply of high-quality omega-3 oils to meet growing global demand, and the transition of Yield10's Omega-3 Camelina program to Nufarm is expected to provide cash runway.

Generated by AI

Sentiment

Of the messages about YTEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	0% -85.44
Bearish	—	—	—	100% +85.44

Bullish· May 9

$YTEN has the potential for significant price appreciation, as evidenced by its trading 50% below cash and 65% below net assets, and 300% below Morningstar's fair value.
The company's upcoming offerings have been shelved, which could lead to a squeeze and drive the price up to $100.
With a relatively small float of 600k shares and a high volume of 500k shares traded, $YTEN is poised for a potential price surge, possibly even exceeding $10.

Bearish· May 9

The company behind $YTEN has withdrawn its 400k float offering, indicating a potential cash shortage.
The stock has a micro float, making it vulnerable to massive price swings and potential squeeze.
The company has less than 1.5MM cash left, suggesting a high likelihood of a fire sale.

Generated by AI

Topics

Of the messages about YTEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· Mar 8

Yield10 Bioscience, Inc. will host its Q4 2017 earnings call on a specific date and time, with an on-demand replay available afterwards.

Announcements· Mar 21

Yield10 Bioscience's Omega-3 Camelina varieties have been determined by USDA-APHIS to be commercially plantable in the United States.
This regulatory milestone may potentially revolutionize the omega-3 market and allow for commercial scale production of omega-3 fatty acids in Camelina.
Yield10 Bioscience's stock, $YTEN, has seen significant price increases in response to this news, with some reports indicating a 125% or 158% rise.

Technical Analysis· Jan 10

$YTEN has broken its previous high of $0.31 and may see a short target afterward.
The stock has formed a bullish engulfing pattern preceding a down trend, and its chart shows a pattern of higher highs and higher lows over the past month.
The stock's volume is big, and its chart looks like it will maintain decent momentum near term, with some analysts expecting a potential reversal trend and a spike up to $0.28+.

Generated by AI

Community

Of the messages about YTEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	4.55%
Newcomers	—	—	—	95.45%

Regulars· Mar 21

The USDA-APHIS has determined that Yield10 Bioscience's Omega-3 Camelina varieties may be planted and bred in the United States.
The float rotation for $YTEN is 5, with an elevated squeeze potential due to the low float of 10.9M shares.
Yield10 Bioscience's stock has traded significantly above average volume, with a 75.93% increase on one day and a 78.85% increase on another day.

Newcomers· Mar 21

Newcomers are discussing the challenges of short selling on $YTEN, with some noting that the high borrow fees can push traders to the sidelines.
New traders are analyzing the float of $YTEN, which is 9 months, and comparing it to other stocks like $SPRC, which has a 1-month float.
New investors are taking a long position on $YTEN, riding the trend, and exiting trades at high reclaim points, citing the trend as their friend.

Generated by AI

Also Discussed

Investors talking about YTEN also mention

#	Name	Attention
1	Arcadia Biosciences Inc.RKDA	0.01%0
2	Houston American Energy Corp.HUSA	0%new
3	GHSI - Guardion Health Sciences, Inc.	——
4	Nanoviricides Inc.NNVC	0%0
5	China Pharma Holdings, Inc.CPHI	0%new
6	Myomo Inc.MYO	0%0
7	TBLT - ToughBuilt Industries, Inc.	——
8	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
9	Daxor CorporationDXR	0%0
10	Achieve Life Sciences, Inc.ACHV	0%new